IL129382A - Method for identifying embryonic cells using antibodies against fetal hemoglobin - Google Patents
Method for identifying embryonic cells using antibodies against fetal hemoglobinInfo
- Publication number
- IL129382A IL129382A IL12938297A IL12938297A IL129382A IL 129382 A IL129382 A IL 129382A IL 12938297 A IL12938297 A IL 12938297A IL 12938297 A IL12938297 A IL 12938297A IL 129382 A IL129382 A IL 129382A
- Authority
- IL
- Israel
- Prior art keywords
- fetal
- antibody
- cells
- hemoglobin
- cell
- Prior art date
Links
- 230000001605 fetal effect Effects 0.000 title claims abstract description 140
- 238000000034 method Methods 0.000 title claims abstract description 87
- 108010054147 Hemoglobins Proteins 0.000 title claims abstract description 45
- 102000001554 Hemoglobins Human genes 0.000 title claims abstract description 45
- 230000003135 anti-embryonic effect Effects 0.000 title claims description 11
- 210000004027 cell Anatomy 0.000 claims abstract description 123
- 210000004369 blood Anatomy 0.000 claims abstract description 51
- 239000008280 blood Substances 0.000 claims abstract description 51
- 210000003924 normoblast Anatomy 0.000 claims abstract description 32
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 28
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 21
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 21
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 16
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims abstract description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims abstract description 7
- 108091005461 Nucleic proteins Proteins 0.000 claims abstract description 7
- 210000003743 erythrocyte Anatomy 0.000 claims description 71
- 239000000523 sample Substances 0.000 claims description 71
- 230000008774 maternal effect Effects 0.000 claims description 46
- 239000012634 fragment Substances 0.000 claims description 18
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 14
- 239000002853 nucleic acid probe Substances 0.000 claims description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 102100030826 Hemoglobin subunit epsilon Human genes 0.000 claims description 9
- 108091005879 Hemoglobin subunit epsilon Proteins 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 239000003298 DNA probe Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 238000000684 flow cytometry Methods 0.000 claims description 7
- 230000002175 menstrual effect Effects 0.000 claims description 7
- 108020003215 DNA Probes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 239000011324 bead Substances 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 108090001008 Avidin Proteins 0.000 claims description 3
- 238000010261 blood fractionation Methods 0.000 claims description 3
- 239000002771 cell marker Substances 0.000 claims description 3
- 108091005886 Hemoglobin subunit gamma Proteins 0.000 claims description 2
- 102100038617 Hemoglobin subunit gamma-2 Human genes 0.000 claims description 2
- 108010090804 Streptavidin Proteins 0.000 claims description 2
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 2
- 239000011159 matrix material Substances 0.000 claims description 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 1
- 108020004518 RNA Probes Proteins 0.000 claims 1
- 239000003391 RNA probe Substances 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 23
- 230000003321 amplification Effects 0.000 abstract description 13
- 210000003754 fetus Anatomy 0.000 abstract description 13
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 13
- 230000005856 abnormality Effects 0.000 abstract description 5
- 230000002759 chromosomal effect Effects 0.000 abstract description 3
- 238000011156 evaluation Methods 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 46
- 108060003951 Immunoglobulin Proteins 0.000 description 20
- 102000018358 immunoglobulin Human genes 0.000 description 20
- 210000000349 chromosome Anatomy 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 210000000265 leukocyte Anatomy 0.000 description 14
- 206010018910 Haemolysis Diseases 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 230000008588 hemolysis Effects 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 8
- 239000000084 colloidal system Substances 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 229940072221 immunoglobulins Drugs 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 230000005945 translocation Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108010044495 Fetal Hemoglobin Proteins 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 238000013019 agitation Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000000834 fixative Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 210000003714 granulocyte Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 210000004700 fetal blood Anatomy 0.000 description 5
- 238000012252 genetic analysis Methods 0.000 description 5
- 102000018146 globin Human genes 0.000 description 5
- 108060003196 globin Proteins 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000007901 in situ hybridization Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 5
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 4
- 201000010374 Down Syndrome Diseases 0.000 description 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 4
- 206010044688 Trisomy 21 Diseases 0.000 description 4
- 238000002669 amniocentesis Methods 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000003793 prenatal diagnosis Methods 0.000 description 4
- 230000008707 rearrangement Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 102000007238 Transferrin Receptors Human genes 0.000 description 3
- 108010033576 Transferrin Receptors Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- -1 haptens Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 238000007899 nucleic acid hybridization Methods 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 210000002993 trophoblast Anatomy 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 102000003846 Carbonic anhydrases Human genes 0.000 description 2
- 108090000209 Carbonic anhydrases Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000037280 Trisomy Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- OUZWUKMCLIBBOG-UHFFFAOYSA-N ethoxzolamide Chemical compound CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1 OUZWUKMCLIBBOG-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000007834 ligase chain reaction Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PVPBBTJXIKFICP-UHFFFAOYSA-N (7-aminophenothiazin-3-ylidene)azanium;chloride Chemical compound [Cl-].C1=CC(=[NH2+])C=C2SC3=CC(N)=CC=C3N=C21 PVPBBTJXIKFICP-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000105975 Antidesma platyphyllum Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 201000003542 Factor VIII deficiency Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102100030387 Hemoglobin subunit zeta Human genes 0.000 description 1
- 108091005905 Hemoglobin subunit zeta Proteins 0.000 description 1
- 208000009292 Hemophilia A Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010076830 Thionins Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- OYTKINVCDFNREN-UHFFFAOYSA-N amifampridine Chemical compound NC1=CC=NC=C1N OYTKINVCDFNREN-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- XFIOKOXROGCUQX-UHFFFAOYSA-N chloroform;guanidine;phenol Chemical compound NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 XFIOKOXROGCUQX-UHFFFAOYSA-N 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 101150015424 dmd gene Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 229950005098 ethoxzolamide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 231100000562 fetal loss Toxicity 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 235000009424 haa Nutrition 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010022155 hemoglobin Portland Proteins 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000020509 sex determination Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001296 transplacental effect Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000036266 weeks of gestation Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
- G01N15/1456—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals
- G01N15/1459—Optical investigation techniques, e.g. flow cytometry without spatial resolution of the texture or inner structure of the particle, e.g. processing of pulse signals the analysis being performed on a sample stream
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Dispersion Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL14569197A IL145691A (en) | 1996-10-21 | 1997-10-20 | Method to identify fetal cells using anti-embryonic hemoglobin antibodies |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/734,556 US5731156A (en) | 1996-10-21 | 1996-10-21 | Use of anti-embryonic hemoglobin antibodies to identify fetal cells |
| PCT/US1997/019447 WO1998018005A1 (en) | 1996-10-21 | 1997-10-20 | Use of anti-embryonic hemoglobin antibodies to identify fetal cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL129382A0 IL129382A0 (en) | 2000-02-17 |
| IL129382A true IL129382A (en) | 2002-09-12 |
Family
ID=24952172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12938297A IL129382A (en) | 1996-10-21 | 1997-10-20 | Method for identifying embryonic cells using antibodies against fetal hemoglobin |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US5731156A (ja) |
| EP (1) | EP1007965B1 (ja) |
| JP (1) | JP4091123B2 (ja) |
| KR (1) | KR100523381B1 (ja) |
| CN (1) | CN1234117A (ja) |
| AT (1) | ATE290210T1 (ja) |
| AU (1) | AU735380B2 (ja) |
| BR (1) | BR9712548A (ja) |
| CA (1) | CA2269327A1 (ja) |
| DE (1) | DE69732662T2 (ja) |
| HK (1) | HK1031255A1 (ja) |
| IL (1) | IL129382A (ja) |
| RU (1) | RU2178703C2 (ja) |
| WO (1) | WO1998018005A1 (ja) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6509192B1 (en) * | 1992-02-24 | 2003-01-21 | Coulter International Corp. | Quality control method |
| US5629147A (en) * | 1992-07-17 | 1997-05-13 | Aprogenex, Inc. | Enriching and identifying fetal cells in maternal blood for in situ hybridization |
| ATE236386T1 (de) * | 1995-11-30 | 2003-04-15 | Chromavision Med Sys Inc | Verfahren zur automatischen bildanalyse biologischer proben |
| US6718053B1 (en) * | 1996-11-27 | 2004-04-06 | Chromavision Medical Systems, Inc. | Method and apparatus for automated image analysis of biological specimens |
| CN1260046A (zh) * | 1997-03-08 | 2000-07-12 | 邓迪大学 | 出生前诊断法 |
| US5962234A (en) * | 1997-10-20 | 1999-10-05 | Applied Imaging Corporation | Use of anti-embryonic epsilon hemoglobin antibodies to identify fetal cells |
| JP2002514762A (ja) * | 1998-05-09 | 2002-05-21 | アイコニシス，インコーポレーテッド | コンピュータによって制御された、胎児細胞を含む希少細胞に基づく診断のための方法および装置 |
| FR2781055B1 (fr) * | 1998-07-09 | 2000-10-13 | Immunotech Sa | Reactif et methode pour la permeabilisation et l'identification des erythrocytes |
| AU4745200A (en) * | 1999-05-25 | 2000-12-12 | Britta Christensen | Isolation and culturing of fetal cells |
| US6692952B1 (en) * | 1999-11-10 | 2004-02-17 | Massachusetts Institute Of Technology | Cell analysis and sorting apparatus for manipulation of cells |
| DE10035433C2 (de) * | 2000-07-20 | 2002-07-18 | Tuma Wolfgang | Schonende Hochanreicherung von fetalen Zellen aus pripherem Blut und Verwendung derselben |
| AU2002357588B2 (en) * | 2001-12-11 | 2008-11-20 | Netech Inc. | Blood cell separation system |
| WO2004029221A2 (en) | 2002-09-27 | 2004-04-08 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
| DK1816461T3 (da) | 2002-10-16 | 2020-04-14 | Streck Laboratories Inc | Fremgangsmåde og indretning til indsamling og sikring af celler til brug for analyse |
| US20040214243A1 (en) * | 2003-04-25 | 2004-10-28 | Beckman Coulter, Inc. | Differential determination of hemoglobins |
| WO2004113877A1 (en) * | 2003-06-13 | 2004-12-29 | The General Hospital Corporation | Microfluidic systems for size based removal of red blood cells and platelets from blood |
| WO2005084374A2 (en) * | 2004-03-03 | 2005-09-15 | The General Hospital Corporation | Magnetic device for isolation of cells and biomolecules in a microfluidic environment |
| US7653260B2 (en) * | 2004-06-17 | 2010-01-26 | Carl Zeis MicroImaging GmbH | System and method of registering field of view |
| US8582924B2 (en) * | 2004-06-30 | 2013-11-12 | Carl Zeiss Microimaging Gmbh | Data structure of an image storage and retrieval system |
| US20070026413A1 (en) * | 2005-07-29 | 2007-02-01 | Mehmet Toner | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US20070196820A1 (en) | 2005-04-05 | 2007-08-23 | Ravi Kapur | Devices and methods for enrichment and alteration of cells and other particles |
| US20070026414A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US20070026417A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US20070026415A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US8921102B2 (en) | 2005-07-29 | 2014-12-30 | Gpb Scientific, Llc | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US20070026416A1 (en) * | 2005-07-29 | 2007-02-01 | Martin Fuchs | Devices and methods for enrichment and alteration of circulating tumor cells and other particles |
| US20090181421A1 (en) * | 2005-07-29 | 2009-07-16 | Ravi Kapur | Diagnosis of fetal abnormalities using nucleated red blood cells |
| US20070059680A1 (en) * | 2005-09-15 | 2007-03-15 | Ravi Kapur | System for cell enrichment |
| US20070059719A1 (en) * | 2005-09-15 | 2007-03-15 | Michael Grisham | Business methods for prenatal Diagnosis |
| US20070059716A1 (en) * | 2005-09-15 | 2007-03-15 | Ulysses Balis | Methods for detecting fetal abnormality |
| US20070059781A1 (en) * | 2005-09-15 | 2007-03-15 | Ravi Kapur | System for size based separation and analysis |
| US20070059683A1 (en) * | 2005-09-15 | 2007-03-15 | Tom Barber | Veterinary diagnostic system |
| US20070059774A1 (en) * | 2005-09-15 | 2007-03-15 | Michael Grisham | Kits for Prenatal Testing |
| US20070059718A1 (en) * | 2005-09-15 | 2007-03-15 | Mehmet Toner | Systems and methods for enrichment of analytes |
| ES2374686T3 (es) | 2007-05-14 | 2012-02-21 | Historx, Inc. | Separación en compartimentos por caracterización de píxel usando agrupamiento de datos de imágenes. |
| CA2690633C (en) * | 2007-06-15 | 2015-08-04 | Historx, Inc. | Method and system for standardizing microscope instruments |
| CA2604317C (en) | 2007-08-06 | 2017-02-28 | Historx, Inc. | Methods and system for validating sample images for quantitative immunoassays |
| CA2596204C (en) * | 2007-08-07 | 2019-02-26 | Historx, Inc. | Method and system for determining an optimal dilution of a reagent |
| US7978258B2 (en) * | 2007-08-31 | 2011-07-12 | Historx, Inc. | Automatic exposure time selection for imaging tissue |
| US8137903B2 (en) | 2007-12-20 | 2012-03-20 | Cytyc Corporation | Method for magnetic separation of red blood cells from a patient sample |
| CA2752838A1 (en) * | 2008-02-18 | 2009-08-27 | Genetic Technologies Limited | Cell processing and/or enrichment methods |
| US20100159506A1 (en) * | 2008-07-25 | 2010-06-24 | Cellscape Corporation | Methods and systems for genetic analysis of fetal nucleated red blood cells |
| US9240043B2 (en) * | 2008-09-16 | 2016-01-19 | Novartis Ag | Reproducible quantification of biomarker expression |
| US20100167271A1 (en) * | 2008-12-30 | 2010-07-01 | Streck, Inc. | Method for screening blood using a preservative that may be in a substantially solid state form |
| US11634747B2 (en) * | 2009-01-21 | 2023-04-25 | Streck Llc | Preservation of fetal nucleic acids in maternal plasma |
| EP2389455A4 (en) * | 2009-01-26 | 2012-12-05 | Verinata Health Inc | METHODS AND COMPOSITIONS FOR IDENTIFYING A FETAL CELL |
| US8231007B2 (en) * | 2009-01-29 | 2012-07-31 | Wark Rickey E | Static classifier cage |
| DK3290530T3 (da) | 2009-02-18 | 2020-12-07 | Streck Inc | Konservering af cellefrie nukleinsyrer |
| WO2010121294A1 (en) * | 2009-04-21 | 2010-10-28 | Genetic Technologies Limited | Methods for obtaining fetal genetic material |
| IN2012DN00715A (ja) * | 2009-06-24 | 2015-06-19 | Health Corp Rambam | |
| WO2011057184A1 (en) * | 2009-11-09 | 2011-05-12 | Streck, Inc. | Stabilization of rna in and extracting from intact cells within a blood sample |
| CN102762712A (zh) | 2010-01-21 | 2012-10-31 | 百赛普有限公司 | 稀有细胞的磁性分离 |
| US8774488B2 (en) | 2010-03-11 | 2014-07-08 | Cellscape Corporation | Method and device for identification of nucleated red blood cells from a maternal blood sample |
| WO2011133625A1 (en) * | 2010-04-20 | 2011-10-27 | Ventana Medical Systems, Inc. | Two-color chromogenic in situ hybridization |
| WO2012151391A2 (en) | 2011-05-04 | 2012-11-08 | Streck, Inc. | Inactivated virus compositions and methods of preparing such compositions |
| EP2794854B1 (en) * | 2011-12-23 | 2018-06-20 | DePuy Synthes Products, Inc. | Detection of human umbilical cord tissue-derived cells |
| WO2013192342A1 (en) * | 2012-06-20 | 2013-12-27 | Celula, Inc. | Materials and methods for processing cell populations |
| WO2013192620A1 (en) | 2012-06-22 | 2013-12-27 | Quantrx Biomedical Corporation | Method for obtaining fetal cells and fetal cellular components |
| DK2925864T3 (en) * | 2012-11-27 | 2019-02-11 | Childrens Medical Ct Corp | DIRECTIONAL TARGETING OF DISTANT BCL11A CONTROLS FOR FETAL HEMOGLOBIN REINUCTION |
| BR112015024266A2 (pt) | 2013-03-27 | 2017-07-18 | Theranos Inc | método para testar uma amostra biológica em um dispositivo, dispositivo e sistema relacionados |
| EP4136972A1 (en) | 2013-07-24 | 2023-02-22 | Streck, Inc. | Compositions and methods for stabilizing circulating tumor cells |
| US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
| CN104977284B (zh) * | 2015-07-03 | 2018-05-29 | 石莹 | 一种胎儿有核红细胞的捕获及鉴定方法 |
| KR101794218B1 (ko) * | 2015-08-19 | 2017-11-07 | 인제대학교 산학협력단 | 비침습적 산전 진단을 위한 산모 혈액 내 유핵 적혈구의 농축 분리 방법 |
| WO2017057076A1 (ja) * | 2015-09-28 | 2017-04-06 | 富士フイルム株式会社 | 有核赤血球の取得方法および有核赤血球の識別方法 |
| US20170145475A1 (en) | 2015-11-20 | 2017-05-25 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
| US11506655B2 (en) | 2016-07-29 | 2022-11-22 | Streck, Inc. | Suspension composition for hematology analysis control |
| JP6234542B1 (ja) | 2016-12-27 | 2017-11-22 | 株式会社 ＴＬ Ｇｅｎｏｍｉｃｓ | 胎児細胞由来染色体ｄｎａの取得方法 |
| KR102313468B1 (ko) | 2017-10-19 | 2021-10-14 | 티엘 제노믹스 인크. | 세포 분류용 칩 |
| CN109115584A (zh) * | 2018-09-10 | 2019-01-01 | 首都医科大学附属北京妇产医院 | 一种检测红细胞中血红蛋白f的检测试剂及其应用 |
| JP7559043B2 (ja) | 2019-07-15 | 2024-10-01 | エー． メナリニ バイオマーカーズ シンガポール プライベート リミテッド | 胎児細胞を単離、検出及び解析する組成物及び方法 |
| CN111948404B (zh) * | 2020-08-03 | 2023-04-07 | 融智生物科技（青岛）有限公司 | 用于筛查地中海贫血的特征蛋白标记组合物、质谱模型及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0500727B1 (en) * | 1989-11-13 | 1998-01-21 | Children's Medical Center Corporation | Non-invasive method for isolation and detection of fetal dna |
| WO1994002646A1 (en) * | 1992-07-17 | 1994-02-03 | Aprogenex Inc. | Enriching and identyfying fetal cells in maternal blood for in situ hybridization |
| US5457024A (en) * | 1993-01-22 | 1995-10-10 | Aprogenex, Inc. | Isolation of fetal erythrocytes |
| AU7474394A (en) * | 1993-07-19 | 1995-02-20 | Aprogenex, Inc. | Enriching and identifying fetal cells in maternal blood for in situ hybridization |
| US5580724A (en) * | 1994-03-25 | 1996-12-03 | Board Of Regents, The University Of Texas System | Differential expansion of fetal stem cells in maternal circulation for use in prenatal genetic analysis |
-
1996
- 1996-10-21 US US08/734,556 patent/US5731156A/en not_active Expired - Lifetime
-
1997
- 1997-10-20 IL IL12938297A patent/IL129382A/en not_active IP Right Cessation
- 1997-10-20 CN CN97199005A patent/CN1234117A/zh active Pending
- 1997-10-20 DE DE69732662T patent/DE69732662T2/de not_active Expired - Fee Related
- 1997-10-20 AT AT97911938T patent/ATE290210T1/de not_active IP Right Cessation
- 1997-10-20 EP EP97911938A patent/EP1007965B1/en not_active Expired - Lifetime
- 1997-10-20 CA CA002269327A patent/CA2269327A1/en not_active Abandoned
- 1997-10-20 AU AU49200/97A patent/AU735380B2/en not_active Ceased
- 1997-10-20 WO PCT/US1997/019447 patent/WO1998018005A1/en active IP Right Grant
- 1997-10-20 JP JP51969498A patent/JP4091123B2/ja not_active Expired - Fee Related
- 1997-10-20 KR KR10-1999-7003439A patent/KR100523381B1/ko not_active IP Right Cessation
- 1997-10-20 RU RU99110373/14A patent/RU2178703C2/ru not_active IP Right Cessation
- 1997-10-20 BR BR9712548-2A patent/BR9712548A/pt not_active Application Discontinuation
-
2000
- 2000-12-14 HK HK00108086A patent/HK1031255A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100523381B1 (ko) | 2005-10-24 |
| BR9712548A (pt) | 1999-12-21 |
| ATE290210T1 (de) | 2005-03-15 |
| EP1007965A4 (en) | 2000-06-14 |
| HK1031255A1 (en) | 2001-06-08 |
| CA2269327A1 (en) | 1998-04-30 |
| IL129382A0 (en) | 2000-02-17 |
| DE69732662T2 (de) | 2005-12-29 |
| EP1007965A1 (en) | 2000-06-14 |
| AU4920097A (en) | 1998-05-15 |
| US5731156A (en) | 1998-03-24 |
| KR20000052662A (ko) | 2000-08-25 |
| AU735380B2 (en) | 2001-07-05 |
| JP4091123B2 (ja) | 2008-05-28 |
| DE69732662D1 (de) | 2005-04-07 |
| JP2001502805A (ja) | 2001-02-27 |
| WO1998018005A1 (en) | 1998-04-30 |
| EP1007965B1 (en) | 2005-03-02 |
| CN1234117A (zh) | 1999-11-03 |
| RU2178703C2 (ru) | 2002-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU735380B2 (en) | Use of anti-embryonic hemoglobin antibodies to identify fetal cells | |
| US5962234A (en) | Use of anti-embryonic epsilon hemoglobin antibodies to identify fetal cells | |
| CA2140278C (en) | Enriching and identyfing fetal cells in maternal blood for in situ hybridization | |
| US5714325A (en) | Prenatal diagnosis by isolation of fetal granulocytes from maternal blood | |
| US5153117A (en) | Fetal cell recovery method | |
| EP0500727B1 (en) | Non-invasive method for isolation and detection of fetal dna | |
| US6210889B1 (en) | Method for enrichment of fetal cells from maternal blood and use of same in determination of fetal sex and detection of chromosomal abnormalities | |
| US5861311A (en) | Preserved, non-infectious control cells prepared by the modulation or modification of normal leukocytes | |
| Davis et al. | Use of monoclonal antibodies and flow cytometry to cluster and analyze leukocyte differentiation molecules | |
| JPH09510875A (ja) | 母親の末梢血からの胎児細胞の培養および単離 | |
| WO1994025873A1 (en) | Methods for enriching fetal progenitor cells from maternal blood | |
| EP0660664B1 (en) | Preserved, non-infectious control cells for use in the identification of a disease through blood testing | |
| Christensen et al. | Studies on the isolation and identification of fetal nucleated red blood cells in the circulation of pregnant women before and after chorion villus sampling | |
| US5763204A (en) | Preparation of preserved, non-infectious control cell for use in the identification of a disease through blood testing | |
| MXPA99003697A (en) | Use of anti-embryonic hemoglobin antibodies to identify fetal cells | |
| US4693967A (en) | Monitoring therapy results in body samples of receptor cells | |
| Bischoff et al. | Prenatal Diagnosis of Chromosomal Abnormalities Using Maternal Blood | |
| AU9718698A (en) | Prenatal diagnosis by isolation of fetal granulocytes from maternal blood | |
| AU7735201A (en) | Fetal cell recovery method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |